Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC
Background/Aims We evaluated the prognostic value of the pretreatment elevation of tumor markers for hepatocellular carcinoma (HCC) in patients who underwent curative treatment. Methods We studied 801 patients who had been diagnosed as initial HCC and fulfilled the following criteria: maximum tumor...
Gespeichert in:
| Veröffentlicht in: | Journal of hepatology 2008-08, Vol.49 (2), p.223-232 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 232 |
|---|---|
| container_issue | 2 |
| container_start_page | 223 |
| container_title | Journal of hepatology |
| container_volume | 49 |
| creator | Toyoda, Hidenori Kumada, Takashi Kaneoka, Yuji Osaki, Yukio Kimura, Toru Arimoto, Akira Oka, Hiroko Yamazaki, Osamu Manabe, Takao Urano, Fumihiro Chung, Hobyung Kudo, Masatoshi Matsunaga, Takashi |
| description | Background/Aims We evaluated the prognostic value of the pretreatment elevation of tumor markers for hepatocellular carcinoma (HCC) in patients who underwent curative treatment. Methods We studied 801 patients who had been diagnosed as initial HCC and fulfilled the following criteria: maximum tumor size, ⩽3 cm; number of tumors, ⩽3; remnant liver function, Child-Pugh class A or B; treated by hepatectomy or locoregional thermal ablation (LTA); and alpha-fetoprotein (AFP), Lens culinaris agglutinin A-reactive fraction of AFP (AFP-L3), and des-gamma carboxy prothrombin (DCP) were measured at diagnosis. We analyzed the effects of elevated tumor markers on patient survival in these 2 distinct groups with different types of treatment, i.e. hepatectomy and LTA. Results By multivariate analysis in 345 patients who underwent hepatectomy, no tumor marker significantly affected decreased survival rate. In the 456 patients who underwent LTA, the elevation of AFP-L3 ( p = 0.0171) and DCP ( p = 0.0004) significantly affected decreased survival rate; DCP elevation had the strongest effect on patient survival. Conclusions The prognostic value of pretreatment tumor marker elevation was different in patients who underwent the curative treatment according to the type of treatment. Pretreatment elevation of AFP-L3 and DCP had prognostic values only in patients treated with LTA. |
| doi_str_mv | 10.1016/j.jhep.2008.04.013 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69302178</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827808003036</els_id><sourcerecordid>69302178</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-db0aeab67a7caf3b53a25a8403f134f486191be90986c5483a4231172df9ab343</originalsourceid><addsrcrecordid>eNp9UsGKFDEQDaK4s6M_4EFy0VuPlU6mOw0iyOC6woKCeg7V6Wo3s92dMUmP7Ff4y6aZwQUPnlJUXr2qeq8YeyFgI0BUb_ab_S0dNiWA3oDagJCP2EpUAAVUSjxmqwzShS5rfcEuY9wDgIRGPWUXQm9rUdZixX5_Cf7H5GNylh9xmIn7nh8CpUCYRpoSH-hIQ1zSaR594COGOwqR9znO7TF5S8MwDxi4xWDd5EfkfuJxDkeXKTn2ifLfHDC5I_EH5qVTzuUw8l8u3fLr3e4Ze9LjEOn5-V2z71cfvu2ui5vPHz_t3t8UVskmFV0LSNhWNdYWe9luJZZb1ApkL6Tqla5EI1pqoNGV3SotUZVSiLrs-gZbqeSavT7xHoL_OVNMZnRxWQQn8nM0VSOhFLXOwPIEtMHHGKg3h-CyBvdGgFlsMHuz2GAWGwwok23IRS_P7HM7UvdQctY9A16dARgtDn3Aybr4F1fCtlYib7Nmb0-4bAEdHQUTbRbMUucC2WQ67_4_x7t_yu3gJpc73tE9xb2fw5RVNsLE0oD5uhzMci-gl1ORlfwDUuy95A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69302178</pqid></control><display><type>article</type><title>Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Collection</source><creator>Toyoda, Hidenori ; Kumada, Takashi ; Kaneoka, Yuji ; Osaki, Yukio ; Kimura, Toru ; Arimoto, Akira ; Oka, Hiroko ; Yamazaki, Osamu ; Manabe, Takao ; Urano, Fumihiro ; Chung, Hobyung ; Kudo, Masatoshi ; Matsunaga, Takashi</creator><creatorcontrib>Toyoda, Hidenori ; Kumada, Takashi ; Kaneoka, Yuji ; Osaki, Yukio ; Kimura, Toru ; Arimoto, Akira ; Oka, Hiroko ; Yamazaki, Osamu ; Manabe, Takao ; Urano, Fumihiro ; Chung, Hobyung ; Kudo, Masatoshi ; Matsunaga, Takashi</creatorcontrib><description>Background/Aims We evaluated the prognostic value of the pretreatment elevation of tumor markers for hepatocellular carcinoma (HCC) in patients who underwent curative treatment. Methods We studied 801 patients who had been diagnosed as initial HCC and fulfilled the following criteria: maximum tumor size, ⩽3 cm; number of tumors, ⩽3; remnant liver function, Child-Pugh class A or B; treated by hepatectomy or locoregional thermal ablation (LTA); and alpha-fetoprotein (AFP), Lens culinaris agglutinin A-reactive fraction of AFP (AFP-L3), and des-gamma carboxy prothrombin (DCP) were measured at diagnosis. We analyzed the effects of elevated tumor markers on patient survival in these 2 distinct groups with different types of treatment, i.e. hepatectomy and LTA. Results By multivariate analysis in 345 patients who underwent hepatectomy, no tumor marker significantly affected decreased survival rate. In the 456 patients who underwent LTA, the elevation of AFP-L3 ( p = 0.0171) and DCP ( p = 0.0004) significantly affected decreased survival rate; DCP elevation had the strongest effect on patient survival. Conclusions The prognostic value of pretreatment tumor marker elevation was different in patients who underwent the curative treatment according to the type of treatment. Pretreatment elevation of AFP-L3 and DCP had prognostic values only in patients treated with LTA.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2008.04.013</identifier><identifier>PMID: 18571271</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Oxford: Elsevier B.V</publisher><subject>Adult ; Aged ; Aged, 80 and over ; alpha-Fetoproteins - metabolism ; Biological and medical sciences ; Biomarkers - blood ; Biomarkers, Tumor - blood ; Carcinoma, Hepatocellular - blood ; Carcinoma, Hepatocellular - mortality ; Carcinoma, Hepatocellular - surgery ; Catheter Ablation ; Curative treatment ; Female ; Gastroenterology and Hepatology ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatectomy ; Hepatocellular carcinoma ; Humans ; Liver Neoplasms - blood ; Liver Neoplasms - mortality ; Liver Neoplasms - surgery ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Neoplasm Recurrence, Local ; Plant Lectins ; Prognosis ; Protein Precursors - blood ; Prothrombin ; Recurrence ; Survival ; Survival Analysis ; Tumor markers ; Tumors</subject><ispartof>Journal of hepatology, 2008-08, Vol.49 (2), p.223-232</ispartof><rights>European Association for the Study of the Liver</rights><rights>2008 European Association for the Study of the Liver</rights><rights>2008 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-db0aeab67a7caf3b53a25a8403f134f486191be90986c5483a4231172df9ab343</citedby><cites>FETCH-LOGICAL-c439t-db0aeab67a7caf3b53a25a8403f134f486191be90986c5483a4231172df9ab343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jhep.2008.04.013$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20574140$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18571271$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><creatorcontrib>Kaneoka, Yuji</creatorcontrib><creatorcontrib>Osaki, Yukio</creatorcontrib><creatorcontrib>Kimura, Toru</creatorcontrib><creatorcontrib>Arimoto, Akira</creatorcontrib><creatorcontrib>Oka, Hiroko</creatorcontrib><creatorcontrib>Yamazaki, Osamu</creatorcontrib><creatorcontrib>Manabe, Takao</creatorcontrib><creatorcontrib>Urano, Fumihiro</creatorcontrib><creatorcontrib>Chung, Hobyung</creatorcontrib><creatorcontrib>Kudo, Masatoshi</creatorcontrib><creatorcontrib>Matsunaga, Takashi</creatorcontrib><title>Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Background/Aims We evaluated the prognostic value of the pretreatment elevation of tumor markers for hepatocellular carcinoma (HCC) in patients who underwent curative treatment. Methods We studied 801 patients who had been diagnosed as initial HCC and fulfilled the following criteria: maximum tumor size, ⩽3 cm; number of tumors, ⩽3; remnant liver function, Child-Pugh class A or B; treated by hepatectomy or locoregional thermal ablation (LTA); and alpha-fetoprotein (AFP), Lens culinaris agglutinin A-reactive fraction of AFP (AFP-L3), and des-gamma carboxy prothrombin (DCP) were measured at diagnosis. We analyzed the effects of elevated tumor markers on patient survival in these 2 distinct groups with different types of treatment, i.e. hepatectomy and LTA. Results By multivariate analysis in 345 patients who underwent hepatectomy, no tumor marker significantly affected decreased survival rate. In the 456 patients who underwent LTA, the elevation of AFP-L3 ( p = 0.0171) and DCP ( p = 0.0004) significantly affected decreased survival rate; DCP elevation had the strongest effect on patient survival. Conclusions The prognostic value of pretreatment tumor marker elevation was different in patients who underwent the curative treatment according to the type of treatment. Pretreatment elevation of AFP-L3 and DCP had prognostic values only in patients treated with LTA.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>alpha-Fetoproteins - metabolism</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>Biomarkers, Tumor - blood</subject><subject>Carcinoma, Hepatocellular - blood</subject><subject>Carcinoma, Hepatocellular - mortality</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Catheter Ablation</subject><subject>Curative treatment</subject><subject>Female</subject><subject>Gastroenterology and Hepatology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatectomy</subject><subject>Hepatocellular carcinoma</subject><subject>Humans</subject><subject>Liver Neoplasms - blood</subject><subject>Liver Neoplasms - mortality</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local</subject><subject>Plant Lectins</subject><subject>Prognosis</subject><subject>Protein Precursors - blood</subject><subject>Prothrombin</subject><subject>Recurrence</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Tumor markers</subject><subject>Tumors</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9UsGKFDEQDaK4s6M_4EFy0VuPlU6mOw0iyOC6woKCeg7V6Wo3s92dMUmP7Ff4y6aZwQUPnlJUXr2qeq8YeyFgI0BUb_ab_S0dNiWA3oDagJCP2EpUAAVUSjxmqwzShS5rfcEuY9wDgIRGPWUXQm9rUdZixX5_Cf7H5GNylh9xmIn7nh8CpUCYRpoSH-hIQ1zSaR594COGOwqR9znO7TF5S8MwDxi4xWDd5EfkfuJxDkeXKTn2ifLfHDC5I_EH5qVTzuUw8l8u3fLr3e4Ze9LjEOn5-V2z71cfvu2ui5vPHz_t3t8UVskmFV0LSNhWNdYWe9luJZZb1ApkL6Tqla5EI1pqoNGV3SotUZVSiLrs-gZbqeSavT7xHoL_OVNMZnRxWQQn8nM0VSOhFLXOwPIEtMHHGKg3h-CyBvdGgFlsMHuz2GAWGwwok23IRS_P7HM7UvdQctY9A16dARgtDn3Aybr4F1fCtlYib7Nmb0-4bAEdHQUTbRbMUucC2WQ67_4_x7t_yu3gJpc73tE9xb2fw5RVNsLE0oD5uhzMci-gl1ORlfwDUuy95A</recordid><startdate>20080801</startdate><enddate>20080801</enddate><creator>Toyoda, Hidenori</creator><creator>Kumada, Takashi</creator><creator>Kaneoka, Yuji</creator><creator>Osaki, Yukio</creator><creator>Kimura, Toru</creator><creator>Arimoto, Akira</creator><creator>Oka, Hiroko</creator><creator>Yamazaki, Osamu</creator><creator>Manabe, Takao</creator><creator>Urano, Fumihiro</creator><creator>Chung, Hobyung</creator><creator>Kudo, Masatoshi</creator><creator>Matsunaga, Takashi</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20080801</creationdate><title>Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC</title><author>Toyoda, Hidenori ; Kumada, Takashi ; Kaneoka, Yuji ; Osaki, Yukio ; Kimura, Toru ; Arimoto, Akira ; Oka, Hiroko ; Yamazaki, Osamu ; Manabe, Takao ; Urano, Fumihiro ; Chung, Hobyung ; Kudo, Masatoshi ; Matsunaga, Takashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-db0aeab67a7caf3b53a25a8403f134f486191be90986c5483a4231172df9ab343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>alpha-Fetoproteins - metabolism</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>Biomarkers, Tumor - blood</topic><topic>Carcinoma, Hepatocellular - blood</topic><topic>Carcinoma, Hepatocellular - mortality</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Catheter Ablation</topic><topic>Curative treatment</topic><topic>Female</topic><topic>Gastroenterology and Hepatology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatectomy</topic><topic>Hepatocellular carcinoma</topic><topic>Humans</topic><topic>Liver Neoplasms - blood</topic><topic>Liver Neoplasms - mortality</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local</topic><topic>Plant Lectins</topic><topic>Prognosis</topic><topic>Protein Precursors - blood</topic><topic>Prothrombin</topic><topic>Recurrence</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Tumor markers</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toyoda, Hidenori</creatorcontrib><creatorcontrib>Kumada, Takashi</creatorcontrib><creatorcontrib>Kaneoka, Yuji</creatorcontrib><creatorcontrib>Osaki, Yukio</creatorcontrib><creatorcontrib>Kimura, Toru</creatorcontrib><creatorcontrib>Arimoto, Akira</creatorcontrib><creatorcontrib>Oka, Hiroko</creatorcontrib><creatorcontrib>Yamazaki, Osamu</creatorcontrib><creatorcontrib>Manabe, Takao</creatorcontrib><creatorcontrib>Urano, Fumihiro</creatorcontrib><creatorcontrib>Chung, Hobyung</creatorcontrib><creatorcontrib>Kudo, Masatoshi</creatorcontrib><creatorcontrib>Matsunaga, Takashi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toyoda, Hidenori</au><au>Kumada, Takashi</au><au>Kaneoka, Yuji</au><au>Osaki, Yukio</au><au>Kimura, Toru</au><au>Arimoto, Akira</au><au>Oka, Hiroko</au><au>Yamazaki, Osamu</au><au>Manabe, Takao</au><au>Urano, Fumihiro</au><au>Chung, Hobyung</au><au>Kudo, Masatoshi</au><au>Matsunaga, Takashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2008-08-01</date><risdate>2008</risdate><volume>49</volume><issue>2</issue><spage>223</spage><epage>232</epage><pages>223-232</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Background/Aims We evaluated the prognostic value of the pretreatment elevation of tumor markers for hepatocellular carcinoma (HCC) in patients who underwent curative treatment. Methods We studied 801 patients who had been diagnosed as initial HCC and fulfilled the following criteria: maximum tumor size, ⩽3 cm; number of tumors, ⩽3; remnant liver function, Child-Pugh class A or B; treated by hepatectomy or locoregional thermal ablation (LTA); and alpha-fetoprotein (AFP), Lens culinaris agglutinin A-reactive fraction of AFP (AFP-L3), and des-gamma carboxy prothrombin (DCP) were measured at diagnosis. We analyzed the effects of elevated tumor markers on patient survival in these 2 distinct groups with different types of treatment, i.e. hepatectomy and LTA. Results By multivariate analysis in 345 patients who underwent hepatectomy, no tumor marker significantly affected decreased survival rate. In the 456 patients who underwent LTA, the elevation of AFP-L3 ( p = 0.0171) and DCP ( p = 0.0004) significantly affected decreased survival rate; DCP elevation had the strongest effect on patient survival. Conclusions The prognostic value of pretreatment tumor marker elevation was different in patients who underwent the curative treatment according to the type of treatment. Pretreatment elevation of AFP-L3 and DCP had prognostic values only in patients treated with LTA.</abstract><cop>Oxford</cop><pub>Elsevier B.V</pub><pmid>18571271</pmid><doi>10.1016/j.jhep.2008.04.013</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8278 |
| ispartof | Journal of hepatology, 2008-08, Vol.49 (2), p.223-232 |
| issn | 0168-8278 1600-0641 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_69302178 |
| source | MEDLINE; Elsevier ScienceDirect Journals Collection |
| subjects | Adult Aged Aged, 80 and over alpha-Fetoproteins - metabolism Biological and medical sciences Biomarkers - blood Biomarkers, Tumor - blood Carcinoma, Hepatocellular - blood Carcinoma, Hepatocellular - mortality Carcinoma, Hepatocellular - surgery Catheter Ablation Curative treatment Female Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Hepatectomy Hepatocellular carcinoma Humans Liver Neoplasms - blood Liver Neoplasms - mortality Liver Neoplasms - surgery Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Neoplasm Recurrence, Local Plant Lectins Prognosis Protein Precursors - blood Prothrombin Recurrence Survival Survival Analysis Tumor markers Tumors |
| title | Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T18%3A23%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prognostic%20value%20of%20pretreatment%20levels%20of%20tumor%20markers%20for%20hepatocellular%20carcinoma%20on%20survival%20after%20curative%20treatment%20of%20patients%20with%20HCC&rft.jtitle=Journal%20of%20hepatology&rft.au=Toyoda,%20Hidenori&rft.date=2008-08-01&rft.volume=49&rft.issue=2&rft.spage=223&rft.epage=232&rft.pages=223-232&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/j.jhep.2008.04.013&rft_dat=%3Cproquest_cross%3E69302178%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69302178&rft_id=info:pmid/18571271&rft_els_id=S0168827808003036&rfr_iscdi=true |